Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person STAT3-activating ALK mutants [cytosol]

Class:Id	CandidateSet:9711944
_displayName	STAT3-activating ALK mutants [cytosol]
_timestamp	2021-03-22 21:38:19
compartment	[Compartment:70101] cytosol
created	[InstanceEdit:9711934] Rothfels, Karen, 2021-01-13
disease	[Disease:1500689] cancer
hasCandidate	[Complex:9716118] EML4(1-780)-p-7Y ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens]
hasMember	[Complex:9699991] NPM1(1-117)-p-7Y ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9711939] KIF5B(2-575)-p-7Y ALK(1063-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9713501] FN1(32-1201)-p-7Y ALK(1022-1620) fusion dimer [plasma membrane] [Homo sapiens] [Complex:9710879] CLTC(2-1634)-p-7Y ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9710884] CLTC(2-1634)-p-7Y ALK(1059-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9700018] EML4(1-223)-p-7Y ALK(1059-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9699994] EML4(1-223)insKMSTREKNSQV -p-7Y ALK(1059-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9700010] EML4(1-486)-p-7Y ALK(1058-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9716117] EML4(1-569)-p-7Y ALK(1078-1620) fusion dimer [cytosol] [Homo sapiens] [Complex:9700020] p-7Y ALK F1174L dimer [plasma membrane] [Homo sapiens] [Complex:9700554] p-7Y ALK K1062M dimer [plasma membrane] [Homo sapiens] [Complex:9723883] p-7Y ALK del224-318 dimer [plasma membrane] [Homo sapiens] [Complex:9723886] p-7Y ALK del318-782 dimer [plasma membrane] [Homo sapiens] [Complex:9699988] p-7Y ALK F1174I dimer [plasma membrane] [Homo sapiens] [Complex:9700563] p-7Y ALK G1128A dimer [plasma membrane] [Homo sapiens] [Complex:9700532] p-7Y ALK I1171N dimer [plasma membrane] [Homo sapiens] [Complex:9700612] p-7Y ALK R1192P dimer [plasma membrane] [Homo sapiens] [Complex:9700603] p-7Y ALK F1245C dimer [plasma membrane] [Homo sapiens] [Complex:9699979] p-7Y ALK R1275Q dimer [plasma membrane] [Homo sapiens]
literatureReference	[LiteratureReference:9699737] Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway [LiteratureReference:9711805] A novel KIF5B-ALK variant in nonsmall cell lung cancer [LiteratureReference:9713378] Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer [LiteratureReference:9710767] Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas [LiteratureReference:9701376] Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer [LiteratureReference:9716071] EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer [LiteratureReference:9700372] Oncogenic mutations of ALK kinase in neuroblastoma [LiteratureReference:9700412] Activating mutations in ALK provide a therapeutic target in neuroblastoma [LiteratureReference:9723824] Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma [LiteratureReference:9723810] Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma [LiteratureReference:9723288] Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma [LiteratureReference:9723817] Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
modified	[InstanceEdit:9713543] Rothfels, Karen, 2021-01-26 [InstanceEdit:9724113] Rothfels, Karen, 2021-03-22 [InstanceEdit:9724129] Rothfels, Karen, 2021-03-22 [InstanceEdit:9724130] Rothfels, Karen, 2021-03-22 [InstanceEdit:9724184] Rothfels, Karen, 2021-03-22
name	STAT3-activating ALK mutants
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9711946] R-HSA-9711944.1
(activeUnit)	[CatalystActivity:9711943] protein tyrosine kinase activity of STAT3-activating ALK mutants:STAT3 [cytosol]
(hasComponent)	[Complex:9711935] STAT3-activating ALK mutants:STAT3 [cytosol] [Homo sapiens] [Complex:9712038] STAT3-activating ALK mutants:p-Y STAT3 [cytosol] [Homo sapiens]
(input)	[Reaction:9712079] ALK mutants bind STAT3 [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by STAT3-activating ALK mutants [cytosol] (9711944)